Patents Examined by Teresa Strzelecka
-
Patent number: 9657333Abstract: The present invention provides a method for detecting a target substance, including the steps of: preparing a complex (hybrid) comprising an aptamer which binds to the target substance, a first nucleic acid fragment comprising a nucleotide sequence complementary to the aptamer and a photoisomerizable molecule bound to a portion of the complementary nucleotide sequence, wherein the aptamer and the first nucleic acid fragment bound with the photoisomerizable molecule form double-stranded nucleotides binding; subjecting the photoisomerizable molecule to a first photoisomerization treatment to destabilize the double-stranded nucleotides binding; forming a complex of the target substance and the aptamer so as to dissolve the destabilized double-stranded nucleotides binding; subjecting the photoisomerizable molecule to a second photoisomerization treatment to restabilize double-stranded nucleotides binding; and detecting dissolution of double-stranded nucleotides binding wherein the first nucleic acid fragment bounType: GrantFiled: February 19, 2013Date of Patent: May 23, 2017Assignee: NEC CoporationInventor: Kimiyasu Takoh
-
Patent number: 9650671Abstract: Compositions, kits, methods and systems for single molecule nucleotide sequencing comprising producing polymerase reactions having lithium that control the median pulse width for incorporated nucleotides are disclosed. The levels of lithium are used to control pulse width while allowing other sequencing parameters to remain within a desirable range.Type: GrantFiled: March 9, 2015Date of Patent: May 16, 2017Assignee: Pacific Biosciences of California, Inc.Inventors: Andrei Fedorov, John Lyle, Keith Bjornson, Jeremiah Hanes
-
Patent number: 9631220Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.Type: GrantFiled: February 9, 2015Date of Patent: April 25, 2017Assignee: Janssen Diagnostics BVBAInventors: Kurt Van Baelen, Lieven Jozef Stuyver, Kevin Karel Florentina Arien
-
Patent number: 9624489Abstract: The invention provides methods for controlling the density of different molecular species on the surface of a solid support. A first mixture of different molecular species is attached to a solid support under conditions to attach each species at a desired density, thereby producing a derivatized support having attached capture molecules. The derivatized support is treated with a second mixture of different molecular species, wherein different molecular species in the second mixture bind specifically to the different capture molecules attached to the solid support. One or more of the capture molecules can be reversibly modified such that the capture molecules have a different activity before and after the second mixture of molecular species are attached. In particular embodiments, the different molecular species are nucleic acids that are reversibly modified to have different activity in an amplification reaction.Type: GrantFiled: February 2, 2015Date of Patent: April 18, 2017Assignee: Illumina, Inc.Inventors: Andrea Sabot, Roberto Rigatti, Min-Jui Richard Shen
-
Patent number: 9611505Abstract: During RNA isolation carrier nucleic acids such as polyA-RNA are used in order to increase the yield of the isolated RNA. The carrier nucleic acids may lead to high molecular weight products which may interfere in subsequent steps, such as reverse transcription, PCR and gel electrophoresis. The present invention therefore refers to a method and a kit for reverse transcription and the use of a blocking nucleic acid molecule for blocking the carrier polyA-RNA.Type: GrantFiled: September 12, 2014Date of Patent: April 4, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Frank Bergmann, Stephanie Froehner
-
Patent number: 9605305Abstract: The present invention reduces primer-dimer amplification in a multiplex polymerase chain reaction (PCR). When a first forward primer (F1) and a second reverse primer (R2) have a complementary region at their 3?ends, primer dimers may form. The present method uses a primer comprising a 5?-end partial sequence or a full sequence of a first forward primer (F1^) in between a first tag (t1) and R2 to reduce the primer-dimer (F1_R2) amplification.Type: GrantFiled: June 16, 2016Date of Patent: March 28, 2017Assignee: PILLAR BIOSCIENCES INC.Inventors: Zhaohui Wang, Gang Song
-
Patent number: 9580758Abstract: A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be HIV.Type: GrantFiled: November 10, 2014Date of Patent: February 28, 2017Inventor: Luc Montagnier
-
Patent number: 9574225Abstract: The invention relates to the preparation of a biological sample for performing verifications and examinations, wherein the aim of the invention is the creation of a method for preparing a biological sample having an improved PCR sensitivity compared to the reference standard having standard PCR without having to raise the cost thereof.Type: GrantFiled: December 23, 2009Date of Patent: February 21, 2017Assignee: QIAGEN GMBHInventors: Ralf Himmelreich, Thomas Rothmann, Roland Fabis, Christoph Erbacher
-
Patent number: 9567625Abstract: Live cells of a microorganism in a test sample are detected by the following steps: a) the step of treating the test sample with a topoisomerase poison and/or a DNA gyrase poison, b) the step of extracting DNA from the test sample, and amplifying a target region of the extracted DNA by PCR, and c) the step of analyzing an amplification product.Type: GrantFiled: October 17, 2014Date of Patent: February 14, 2017Assignee: MORINAGA MILK INDUSTRY CO., LTD.Inventors: Shinichi Yoshida, Takashi Soejima
-
Patent number: 9568839Abstract: The invention relates to a method for producing polymers, in particular synthetic nucleic acid double strands of optional sequence, comprising the steps: (a) provision of a support having a surface area which contains a plurality of individual reaction areas, (b) location-resolved synthesis of nucleic acid fragments having in each case different base sequences in several of the individual reaction areas, and (c) detachment of the nucleic acid fragments from individual reaction areas.Type: GrantFiled: March 9, 2009Date of Patent: February 14, 2017Assignee: Synthetic Genomics, Inc.Inventors: Peer F. Stähler, Cord F. Stähler, Manfred Müller
-
Patent number: 9562250Abstract: A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor. The recombination intermediate is treated with a high fidelity polymerase to permit the replication and amplification of the target nucleic acid sequence. In preferred embodiments, the polymerase comprises a polymerase holoenzyme. In further preferred embodiments, the recombination factor is bacteriophage T4 UvsX protein or homologs from other species, and the polymerase holoenzyme comprises a polymerase enzyme, a clamp protein and a clamp loader protein, derived from viral, bacteriophage, prokaryotic, archaebacterial, or eukaryotic systems.Type: GrantFiled: June 24, 2014Date of Patent: February 7, 2017Assignee: The Penn State Research FoundationInventors: Stephen J Benkovic, Frank Salinas
-
Patent number: 9558320Abstract: Disclosed herein are compositions and methods relevant to a novel Drug Metabolism Reserve Physiotype to determine the metabolic capacity of a human individual. The Drug Metabolism Reserve Physiotype allows the determination of the innate metabolic capacity of the patient relevant to antidepressant and stimulant treatment and can be predicted and diagnosed simply from a blood sample. In the disclosed method, an individual is genotyped for a plurality of polymorphisms in a gene encoding CYP2C9, a gene encoding CYP2C19 and a gene encoding CYP2D6, and the genotypes are used to produce four novel indices, which relate to the metabolic capacity of the human individual.Type: GrantFiled: October 22, 2010Date of Patent: January 31, 2017Assignee: GENOMAS, INC.Inventors: Gualberto Ruano, David Victor Villagra, Mohan Ranjit Kumar Kocherla, Andreas Windemuth, John W. Goethe
-
Patent number: 9546399Abstract: The present invention provides methods, compositions and kits for detecting duplicate sequencing reads. In some embodiments, the duplicate sequencing reads are removed.Type: GrantFiled: November 13, 2014Date of Patent: January 17, 2017Assignee: NUGEN TECHNOLOGIES, INC.Inventors: Douglas Amorese, Jonathan Scolnick, Ben Schroeder
-
Patent number: 9534258Abstract: The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.Type: GrantFiled: August 29, 2014Date of Patent: January 3, 2017Assignee: PACIFIC EDGE LIMITEDInventors: Michael Alan Black, Jonathan Cebon, Parry John Guilford, Thomas John
-
Patent number: 9523120Abstract: A nucleic acid amplification method is provided, along with kits useful in performing the amplification method.Type: GrantFiled: June 14, 2012Date of Patent: December 20, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventor: Abhay N. Vats
-
Patent number: 9512477Abstract: The invention discloses methods and apparatus for characterizing trace nucleic acids that are biomarkers for disease. The methods and apparatus provide increased sensitivity to such trace nucleic acids, and allow analysis of nucleic acids present in a sample at only 0.01% of the wild-type sequences. The methods and apparatus are also designed for straightforward multiplexing, thus allowing pooling of clinical samples.Type: GrantFiled: May 3, 2013Date of Patent: December 6, 2016Assignees: Boreal Genomics Inc., The University of British ColumbiaInventors: Andrea Marziali, Matthew Wiggin, Gosuke Shibahara, Valentina S. Vysotskaia
-
Patent number: 9512475Abstract: The present disclosure relates to a highly specific and sensitive method of detecting host cell impurities in a biological sample by using quantitative real time polymerase chain reaction (q PCR). The present disclosure also provides novel designed primer and probe to amplify only the specific Alu family of dispersed repetitive sequences from Chinese hamster ovary cells used for expression of therapeutic proteins.Type: GrantFiled: March 6, 2012Date of Patent: December 6, 2016Assignee: Biocon LimitedInventors: Rahul Sharad Fadnis, Reena Nichinmetla Raghunandan
-
Patent number: 9506109Abstract: The current invention relates to a method for analysis of a population of micro-organisms (e.g. bacterial population) of different taxonomic groups in an environment suspected to contain said bacteria, primers, primer sets and pair of primer sets suitable for use is such method, and use of such method in determining the effect of external factors like drugs, nutrients and pesticides on bacterial populations of different taxonomic groups.Type: GrantFiled: April 17, 2008Date of Patent: November 29, 2016Assignee: Microbiome LimitedInventors: Paul Hendrik Maria Savelkoul, Andries Edward Budding
-
Patent number: 9487829Abstract: Error rates in massively parallel sequencing instruments are generally too high to allow confident identification of rare variants. An approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.Type: GrantFiled: July 30, 2015Date of Patent: November 8, 2016Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Isaac Kinde
-
Patent number: 9476095Abstract: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation.Type: GrantFiled: April 12, 2012Date of Patent: October 25, 2016Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Isaac Kinde